Pollen Allergy - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 103 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Pollen Allergy - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Pollen Allergy - Pipeline Review, H2 2014', provides an overview of the Pollen Allergy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pollen Allergy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pollen Allergy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Pollen Allergy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pollen Allergy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pollen Allergy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Pollen Allergy Overview 10
Therapeutics Development 11
Pipeline Products for Pollen Allergy - Overview 11
Pipeline Products for Pollen Allergy - Comparative Analysis 12
Pollen Allergy - Therapeutics under Development by Companies 13
Pollen Allergy - Therapeutics under Investigation by Universities/Institutes 15
Pollen Allergy - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Pollen Allergy - Products under Development by Companies 19
Pollen Allergy - Products under Investigation by Universities/Institutes 21
Pollen Allergy - Companies Involved in Therapeutics Development 22
ALK-Abello A/S 22
Allergopharma Joachim Ganzer KG 23
Allergy Therapeutics plc 24
Anergis SA 25
Biomay AG 26
BioTech Tools s.a. 27
Circassia Pharmaceuticals plc 28
HAL Allergy BV 29
Immunomic Therapeutics, Inc. 30
Japan Tobacco Inc. 31
Laboratorios LETI S.L. 32
REGiMMUNE Corporation 33
Roxall Medizin GmbH 34
Stallergenes S.A. 35
Pollen Allergy - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Combination Products 37
Assessment by Target 38
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
ALK Birch Pollen Vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
AllerG - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Allergen Extract Of Phleum Pratense - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
AllerJ - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
AllerT - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Avanz Phleum Pratense - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Birch-SPIRE - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
BM-31 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
BM-32 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
clustoid wiesenlieschgras - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Drug for Birch Pollen Allergy - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Drug for Japanese Cedar Pollen Allergy - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Drugs for Cedar Pollen Allergy - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
gpASIT + TM - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
grass allergy vaccine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Grass-SPIRE - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Japanese cedar hypoallergenic vaccine - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
JCC-LAMP-Vax - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
JRC-LAMP-Vax - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
MC-LAMP-Vax - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Multi-LAMP-Vax - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
PL-102 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Pollinex Quattro Grass - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Pollinex Quattro Japanese Cedar - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Pollinex Quattro Tree - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
rBet v1 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
rBet v1-FV - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
RGI-1001 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
timothy grass pollen allergen extract - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
TO-206 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Vaccine for Cedar Pollen Allergy - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Vaccine for Cedar Pollen Allergy - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Vaccine for Pollen Allergy - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Pollen Allergy - Recent Pipeline Updates 87
Pollen Allergy - Dormant Projects 93
Pollen Allergy - Discontinued Products 95
Pollen Allergy - Product Development Milestones 96
Featured News & Press Releases 96
Dec 11, 2014: Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT 96
Sep 16, 2014: Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT 96
Apr 23, 2014: Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT 97
Apr 14, 2014: ALK announces FDA approval for Merck's grass sublingual allergy immunotherapy tablet GRASTEK 97
Feb 27, 2014: Phase IIb Results of Anergis� Lead Compound AllerT to be Presented at 2014 AAAAI Annual Meeting in San Diego 98
Feb 18, 2014: Health Canada approves submission of CTA to progress ultra-short course Pollinex Quattro Grass efficacy study 98
Feb 03, 2014: Merck Announces Canadian Approval of GRASTEK (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet) 99
Dec 16, 2013: Biomay AG successfully completes interim analysis of phase IIb study with the innovative 3rd generation grass pollen allergy vaccine BM32 99
Dec 12, 2013: FDA Advisory Committee meeting unanimously recommends approval of GRASTEK 100
Dec 10, 2013: ALK announces posting of briefing documents for FDA Advisory Committee meeting on the grass sublingual AIT tablet 100
Appendix 102
Methodology 102
Coverage 102
Secondary Research 102
Primary Research 102
Expert Panel Validation 102
Contact Us 103
Disclaimer 103

List of Tables
Number of Products under Development for Pollen Allergy, H2 2014 11
Number of Products under Development for Pollen Allergy - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 14
Number of Products under Investigation by Universities/Institutes, H2 2014 15
Comparative Analysis by Late Stage Development, H2 2014 16
Comparative Analysis by Clinical Stage Development, H2 2014 17
Comparative Analysis by Early Stage Development, H2 2014 18
Products under Development by Companies, H2 2014 19
Products under Development by Companies, H2 2014 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2014 21
Pollen Allergy - Pipeline by ALK-Abello A/S, H2 2014 22
Pollen Allergy - Pipeline by Allergopharma Joachim Ganzer KG, H2 2014 23
Pollen Allergy - Pipeline by Allergy Therapeutics plc, H2 2014 24
Pollen Allergy - Pipeline by Anergis SA, H2 2014 25
Pollen Allergy - Pipeline by Biomay AG, H2 2014 26
Pollen Allergy - Pipeline by BioTech Tools s.a., H2 2014 27
Pollen Allergy - Pipeline by Circassia Pharmaceuticals plc, H2 2014 28
Pollen Allergy - Pipeline by HAL Allergy BV, H2 2014 29
Pollen Allergy - Pipeline by Immunomic Therapeutics, Inc., H2 2014 30
Pollen Allergy - Pipeline by Japan Tobacco Inc., H2 2014 31
Pollen Allergy - Pipeline by Laboratorios LETI S.L., H2 2014 32
Pollen Allergy - Pipeline by REGiMMUNE Corporation, H2 2014 33
Pollen Allergy - Pipeline by Roxall Medizin GmbH, H2 2014 34
Pollen Allergy - Pipeline by Stallergenes S.A., H2 2014 35
Assessment by Monotherapy Products, H2 2014 36
Assessment by Combination Products, H2 2014 37
Number of Products by Stage and Target, H2 2014 38
Number of Products by Stage and Route of Administration, H2 2014 40
Number of Products by Stage and Molecule Type, H2 2014 42
Pollen Allergy Therapeutics - Recent Pipeline Updates, H2 2014 87
Pollen Allergy - Dormant Projects, H2 2014 93
Pollen Allergy - Dormant Projects (Contd..1), H2 2014 94
Pollen Allergy - Discontinued Products, H2 2014 95